Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annals of Oncology

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdp460PMID 19875761PMCID PMC2875547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols

  2009cited by this paper
• High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.

  2008cited by this paper
• The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression.

  2007cited by this paper
• MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes.

  2007cited by this paper
• Biologic predictors in follicular lymphoma: Importance of markers of immune response

  2007influential reference
• A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.

  2007cited by this paper
• CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features.

  2007cited by this paper
• A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone

  2007cited by this paper
• High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.

  2006cited by this paper
• The architectural pattern of FOXP3*T cells is an independent predictor of survival in patients with follicular lymphoma (FL)

  2006cited by this paper
• Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.

  2006cited by this paper
• Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.

  2006cited by this paper
• Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.

  2006cited by this paper
• Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.

  2006cited by this paper
• Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

  2006cited by this paper
• Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t

  2005cited by this paper
• Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

  2005cited by this paper
• Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems.

  2005cited by this paper
• CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

  2005cited by this paper
• New treatment options have changed the survival of patients with follicular lymphoma.

  2005cited by this paper
• Improved survival of follicular lymphoma patients in the United States.

  2005cited by this paper
• Follicular lymphoma international prognostic index.

  2004influential reference
• Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

  2004cited by this paper
• A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.

  2003influential reference
• Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

  2003cited by this paper
• E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues

  2002cited by this paper
• Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry

  2001cited by this paper
• Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.

  2000cited by this paper
• A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells.

  2000cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper

• Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma

  2025cites this paper
• High Ki-67 Expression Predicting a Risk Factor for the Progression of Disease within 24 Months and Microenvironment in Follicular Lymphoma

  2024cites this paper
• Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review

  2024cites this paper
• The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma

  2023cites this paper
• Genetics of Transformed Follicular Lymphoma

  2022cites this paper
• Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification

  2022cites this paper
• Predicting early progression in follicular lymphoma

  2021cites this paper
• An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy

  2021cites this paper
• Immune infiltrate diversity confers a good prognosis in follicular lymphoma

  2021cites this paper
• Prognostic Value of Peripheral Blood Lymphocyte/monocyte Ratio in Lymphoma

  2021cites this paper
• Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.

  2020cites this paper
• Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.

  2020cites this paper
• Follicular and Mantle Cell Lymphomas: Technical and Interpretive Considerations; Karyotyping, FISH, Chromosomal Microarray, Sequencing, B Cell Clonality, Minimal Residual Disease

  2020cites this paper
• Role of Microenvironment in Non-Hodgkin Lymphoma

  2020cites this paper
• Follicular Lymphoma and Mantle Cell Lymphoma: Pathobiology, Diagnosis and Treatment

  2020cites this paper
• MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma

  2018cites this paper
• Tumor Microenvironment in T-Cell Lymphomas.

  2018cites this paper
• Can histologic transformation of follicular lymphoma be predicted and prevented?

  2017cites this paper
• Transformed follicular lymphoma

  2017cites this paper
• Diagnosis of Pediatric-Type Follicular Lymphoma in Young Adults (Own Data)

  2017cites this paper
• The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era

  2016cites this paper
• Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment

  2016cites this paper
• Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node

  2016cites this paper
• Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.

  2016cites this paper
• Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.

  2016cites this paper
• FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma

  2016cites this paper
• Pathology of B-cell lymphomas: diagnosis and biomarker discovery.

  2015cites this paper
• Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP

  2015cites this paper
• Cell of origin of transformed follicular lymphoma.

  2015cites this paper
• Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma

  2014cites this paper
• Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma

  2014cites this paper
• Indolent lymphoma: follicular lymphoma and the microenvironment-insights from gene expression profiling.

  2014cites this paper
• Cutaneous Double-Hit B-Cell Lymphoma: An Aggressive Form of B-Cell Lymphoma With a Propensity for Cutaneous Dissemination

  2014cites this paper
• Human Cancer Biology Pattern of CD 14 þ Follicular Dendritic Cells and PD 1 þ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma

  2014cites this paper
• Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.

  2014influential citation
• The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium

  2014cites this paper
• Dissecting follicular lymphoma: high versus low risk.

  2013cites this paper
• Cellular composition of the tumor microenvironment.

  2013cites this paper
• A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

  2013cites this paper
• RESEARCH COMMUNICATION Elevated Circulating CD19 + Lymphocytes Predict Survival Advantage in Patients with Gastric Cancer

  2012cites this paper
• Pathogenesis of follicular lymphoma.

  2012cites this paper
• Elevated circulating CD19+ lymphocytes predict survival advantage in patients with gastric cancer.

  2012cites this paper
• Elevated Circulating CD 19 + Lymphocytes Predict Survival Advantage in Patients with Gastric Cancer

  2012cites this paper
• The tumor microenvironment in follicular lymphoma.

  2012cites this paper
• Absolute monocyte count identifies high-risk patients with lymphomas: “absolutely” simple and “counts” mean a lot!

  2012cites this paper
• Prognostic importance of the tumour microenvironment in follicular lymphoma patients treated with immunochemotherapy

  2011cites this paper
• The microenvironment in follicular lymphoma.

  2011cites this paper
• Prognostic information from nonmalignant and malignant lymphocytes in follicular lymphoma in relation to therapy

  2011cites this paper
• Follicular lymphoma: still Six characters in search of an author?

  2011cites this paper
• Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?

  2010cites this paper
• The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas

  2010cites this paper
• Implications of the tumor microenvironment on survival and disease response in follicular lymphoma

  2010cites this paper